

# World Journal of *Experimental Medicine*

Quarterly Volume 14 Number 3 September 20, 2024



**EDITORIAL**

**Khosla D, Singh PK, Chhabria BA, Kataria V, Singh N, Kapoor R.** Malignant pleural mesothelioma: The disdained member of thoracic oncology! *World J Exp Med* 2024; 14(3): 91739 [DOI: [10.5493/wjem.v14.i3.91739](https://doi.org/10.5493/wjem.v14.i3.91739)]

**OPINION REVIEW**

**Kokudeva M, Vichev M, Naseva E, Miteva DG, Velikova T.** Artificial intelligence as a tool in drug discovery and development. *World J Exp Med* 2024; 14(3): 96042 [DOI: [10.5493/wjem.v14.i3.96042](https://doi.org/10.5493/wjem.v14.i3.96042)]

**REVIEW**

**English KJ.** Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment. *World J Exp Med* 2024; 14(3): 98525 [DOI: [10.5493/wjem.v14.i3.98525](https://doi.org/10.5493/wjem.v14.i3.98525)]

**MINIREVIEWS**

**Rai P, Garain T, Gupta D.** Phytochemical analysis of *Tinospora cordifolia* and *Withania somnifera* and their therapeutic activities with special reference to COVID-19. *World J Exp Med* 2024; 14(3): 95512 [DOI: [10.5493/wjem.v14.i3.95512](https://doi.org/10.5493/wjem.v14.i3.95512)]

**Rahmati M, Moghtaderi H, Mohammadi S, Al-Harrasi A.** Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities. *World J Exp Med* 2024; 14(3): 96269 [DOI: [10.5493/wjem.v14.i3.96269](https://doi.org/10.5493/wjem.v14.i3.96269)]

**El Assaad N, Chebly A, Salame R, Achkar R, Bou Atme N, Akouch K, Rafoul P, Hanna C, Abou Zeid S, Ghosn M, Khalil C.** Anti-aging based on stem cell therapy: A scoping review. *World J Exp Med* 2024; 14(3): 97233 [DOI: [10.5493/wjem.v14.i3.97233](https://doi.org/10.5493/wjem.v14.i3.97233)]

**ORIGINAL ARTICLE****Retrospective Study**

**Patel B, Khadke S, Mahajan K, Dhingra A, Trivedi R, Brar SS, Dixit S, Periwal V, Chauhan S, Desai R.** Association of cannabis use disorder with atrial fibrillation in young men without concomitant tobacco use: Insights from nationwide propensity matched analysis. *World J Exp Med* 2024; 14(3): 93742 [DOI: [10.5493/wjem.v14.i3.93742](https://doi.org/10.5493/wjem.v14.i3.93742)]

**Viswas A, Dabla PK, Shrivastav D, Gupta S, Yadav M, Yadav S, Koner BC.** SCN1A rs6732655A/T polymorphism: Diagnostic and therapeutic insights for drug-resistant epilepsy. *World J Exp Med* 2024; 14(3): 94999 [DOI: [10.5493/wjem.v14.i3.94999](https://doi.org/10.5493/wjem.v14.i3.94999)]

**Chaiwisitkun A, Muengtawepong S.** Platelet-to-neutrophil ratio predicts hemorrhagic transformation and unfavorable outcomes in acute ischemic stroke with intravenous thrombolysis. *World J Exp Med* 2024; 14(3): 95540 [DOI: [10.5493/wjem.v14.i3.95540](https://doi.org/10.5493/wjem.v14.i3.95540)]

**Clinical and Translational Research**

Bangolo AI, Auda A, Bukasa-Kakamba J, Bhakta N, Dey S, Iilhoru A, Reddy G, Alqinai B, Sidiqui A, Sekhon I, Khatiashvili B, Abbas I, Kunnel S, Jarri A, Martinez E, Daoud D, Gupta I, Gompa H, Pender S, Aljaberi D, Aljanaahi H, Kunnel SS, Xiao Y, Jung Y, Nagpaul S, Naz A, Mallela T, Maung PM, Khalaf IY, Kim S, Alrestom R, Gajera A, Alkealy H, Kansal D, Dhall S, Satheesha S, Weissman S, Fwelo P. Interaction between tumor stage and age on survival outcomes of patients with anaplastic thyroid cancer. *World J Exp Med* 2024; 14(3): 93869 [DOI: 10.5493/wjem.v14.i3.93869]

**Basic Study**

Pierzynowska K, Wychowański P, Zaworski K, Woliński J, Donaldson J, Szkopek D, Roszkowicz-Ostrowska K, Kondej A, Pierzynowski SG. Amylase intrapancreatic infusion delays insulin release during an intravenous glucose tolerance test, proof of acini-islet-acinar interactions. *World J Exp Med* 2024; 14(3): 92589 [DOI: 10.5493/wjem.v14.i3.92589]

**SYSTEMATIC REVIEWS**

Amedu AN. Addressing trauma, post-traumatic stress disorder, and post-traumatic growth in breast cancer patients. *World J Exp Med* 2024; 14(3): 95565 [DOI: 10.5493/wjem.v14.i3.95565]

**LETTER TO THE EDITOR**

Gana N, Huluta I, Gica N. Hypoglycaemia in screening oral glucose tolerance test in pregnancy with low birth weight fetus. *World J Exp Med* 2024; 14(3): 96720 [DOI: 10.5493/wjem.v14.i3.96720]

**ABOUT COVER**

Peer Reviewer of *World Journal of Experimental Medicine*, Rachid AIT ADDI, MD, PhD, Epidemiologist-Anthropobiologist, Research Scientist, Laboratory Associate member of Human Ecology, Department of Biology, University of Cadi Ayyad Marrakesh, Morocco. dr.rachid.aitaddi@gmail.com.

**AIMS AND SCOPE**

The primary aim of the *World Journal of Experimental Medicine (WJEM, World J Exp Med)* is to provide scholars and readers from various fields of experimental medicine with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJEM* mainly publishes articles reporting research results and findings obtained in the field of experimental medicine and covering a wide range of topics including clinical laboratory medicine (applied and basic research in hematology, body fluid examination, cytomorphology, genetic diagnosis of hematological disorders, thrombosis and hemostasis, and blood typing and transfusion), biochemical examination (applied and basic research in laboratory automation and information system, biochemical methodology, and biochemical diagnostics), etc.

**INDEXING/ABSTRACTING**

The *WJEM* is now abstracted and indexed in PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The *WJEM*'s CiteScore for 2023 is 1.7 and Scopus CiteScore rank 2023: Internal medicine is 109/167.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Wen-Bo Wang*; Production Department Director: *Xu Guo*; Cover Editor: *Ji-Hong Liu*.

**NAME OF JOURNAL**

*World Journal of Experimental Medicine*

**ISSN**

ISSN 2220-315x (online)

**LAUNCH DATE**

December 20, 2011

**FREQUENCY**

Quarterly

**EDITORS-IN-CHIEF**

Jian Wu

**EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**

Fang Gong

**EDITORIAL BOARD MEMBERS**

<https://www.wjnet.com/2220-315x/editorialboard.htm>

**PUBLICATION DATE**

September 20, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**PUBLISHING PARTNER**

Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital

**INSTRUCTIONS TO AUTHORS**

<https://www.wjnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjnet.com/bpg/gerinfo/208>

**POLICY OF CO-AUTHORS**

<https://www.wjnet.com/bpg/GerInfo/310>

**ARTICLE PROCESSING CHARGE**

<https://www.wjnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

**PUBLISHING PARTNER'S OFFICIAL WEBSITE**

<http://www.smh.cc/home2020/page/index/index.html>



# Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities

Mina Rahmati, Hassan Moghtaderi, Saeed Mohammadi, Ahmed Al-Harrasi

**Specialty type:** Immunology

**Provenance and peer review:**  
Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade B

**Novelty:** Grade A

**Creativity or Innovation:** Grade A

**Scientific Significance:** Grade B

**P-Reviewer:** Wang Z

**Received:** May 1, 2024

**Revised:** May 26, 2024

**Accepted:** June 14, 2024

**Published online:** September 20, 2024

**Processing time:** 119 Days and 23 Hours



**Mina Rahmati**, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Tehran, Iran

**Hassan Moghtaderi, Saeed Mohammadi, Ahmed Al-Harrasi**, Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Ad Dakhiliyah, Oman

**Co-first authors:** Mina Rahmati and Hassan Moghtaderi.

**Co-corresponding authors:** Saeed Mohammadi and Ahmed Al-Harrasi.

**Corresponding author:** Ahmed Al-Harrasi, PhD, Full Professor, Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, PO Box 33, Postal Code 616, Nizwa, Oman. [aharrasi@unizwa.edu.om](mailto:aharrasi@unizwa.edu.om)

## Abstract

Esophageal squamous cell carcinoma (ESCC) is a substantial global health burden. Immune escape mechanisms are important in ESCC progression, enabling cancer cells to escape the surveillance of the host immune system. One key player in this process is the Aryl Hydrocarbon Receptor (AhR), which influences multiple cellular processes, including proliferation, differentiation, metabolism, and immune regulation. Dysregulated AhR signaling participates in ESCC development by stimulating carcinogenesis, epithelial-mesenchymal transition, and immune escape. Targeting AhR signaling is a potential therapeutic approach for ESCC, with AhR ligands showing efficacy in preclinical studies. Additionally, modification of AhR ligands and combination therapies present new opportunities for therapeutic intervention. This review aims to address the knowledge gap related to the role of AhR signaling in ESCC pathogenesis and immune escape.

**Key Words:** Esophageal squamous cell carcinoma; Aryl hydrocarbon receptor; Immune escape; Tumor microenvironment; Immunosuppression; Therapeutic targeting

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Esophageal squamous cell carcinoma (ESCC) utilizes immune escape mechanisms, including major histocompatibility complex downregulation and immune checkpoint manipulation, enhancing tumor progression. The aryl hydrocarbon receptor (AhR), crucial in health and disease, significantly influences ESCC development and immune evasion through carcinogenic pathways. AhR activation triggers proliferation, inhibits apoptosis, and induces epithelial-mesenchymal transition. Moreover, AhR suppresses effector T cells and enrolls immunosuppressive myeloid cells. Therapeutic AhR targeting with AhR ligands showed promise in inhibiting tumor growth, controlling the immune microenvironment, and enhancing treatment efficacy. Combining AhR-targeted therapies with conventional treatments or dietary interventions has the potential to improve ESCC patient outcomes.

**Citation:** Rahmati M, Moghtaderi H, Mohammadi S, Al-Harrasi A. Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities. *World J Exp Med* 2024; 14(3): 96269

**URL:** <https://www.wjgnet.com/2220-315x/full/v14/i3/96269.htm>

**DOI:** <https://dx.doi.org/10.5493/wjem.v14.i3.96269>

## INTRODUCTION

Esophageal squamous cell carcinoma (ESCC), a severe malignancy of the esophagus, shows a significant global health burden (ESCC is the eighth most common cancer globally)[1]. It shows a notable geographical variation, with particularly high incidence rates in East Asia, Central Asia, and certain regions of Africa[2].

ESCC emerges through a multistep process involving progressive genetic and molecular alterations within the esophageal epithelium[3]. Chronic exposure to established carcinogens, such as tobacco smoke and excessive alcohol consumption, triggers cellular damage and initiates a cascade of events leading to uncontrolled proliferation and malignant transformation[4]. These factors can lead to point mutations in tumor suppressor genes such as p53, which regulate cell cycle progression and DNA repair[5]. Moreover, amplification of oncogenes, such as cyclin D1, promote cell cycle dysregulation and uncontrolled growth[6]. Furthermore, epigenetic modifications, such as DNA methylation and histone acetylation configurations, can inhibit tumor suppressor genes and provide a pro-tumorigenic microenvironment[7]. These genetic and molecular aberrations interfere with normal cellular processes, leading to the development of pre-cancerous lesions characterized by squamous epithelial hyperplasia and dysplasia. If left unchecked, these pre-cancerous lesions may progress to invasive ESCC.

Despite advancements in treatment procedures, ESCC prognosis is still poor, emphasizing the need for a better understanding of the main processes that stimulate tumorigenesis and immune escape.

## IMMUNE ESCAPE: A CANCEROUS DEFENSE MECHANISM

ESCC development is counterbalanced by the host immune system, which employs a two-edged plan for immune surveillance, including innate and adaptive immunity[8]. The ability of cancer cells to evade the detection of immune system and elimination is a hallmark of tumor progression[9]. In ESCC, the immune escape demonstrates through a sophisticated connection of various mechanisms utilized by tumor cells to create a microenvironment that protects them from immune attack[10].


To escape the strong immune surveillance system, ESCC cells organize a multi-dimensional immune escape program (Figure 1). One of the key mechanisms includes downregulation of major histocompatibility complex (MHC) molecules on the cell surface[11]. MHC molecules function as antigen presentation platforms, allowing T cells to recognize and eliminate foreign or abnormal cells. By reducing MHC expression, ESCC cells become undetectable to the immune system, making them resistant to T cell-mediated cytotoxicity[12].

Furthermore, ESCC cells actively modulate the tumor microenvironment to create an immunosuppressive state[13]. They achieve this by secreting chemokines and cytokines that recruit and activate regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs)[10]. The suppressive cell populations directly inhibit the T lymphocytes (CTLs) and suppress the immune response[8].

Immune escape in ESCC also involves utilization of immune checkpoint pathways. These pathways, mediated by molecules such as PD-L1 and CTLA-4, act as a regulatory brake on the immune system to prevent excessive immune activation and autoimmunity[13,14]. ESCC cells can upregulate the expression of these checkpoint ligands, allowing them to bind to their corresponding receptors on T cells and effectively deactivate the anti-tumor T cell response[15].

In addition to the previously mentioned mechanisms, ESCC cells show a flexible immune escape repertoire. They can express ligands that bind to inhibitory receptors on T cells, leading to T cell exhaustion and dysfunction[13]. ESCC cells can also reprogram their metabolism to escape immune recognition and resist immune-mediated cytotoxicity[10]. Furthermore, they can produce immunosuppressive enzymes, such as indoleamine 2,3-dioxygenase, which reduces essential amino acids required for T cell activation and function, disabling the anti-tumor immune response[16].

By using these diverse immune escape methods, ESCC cells create a microenvironment that protects them from immune attack and promotes tumor progression. Understanding these mechanisms is crucial for developing novel therapeutic strategies that can enhance the anti-tumor immune response and improve patient outcomes.



**Figure 1 Aryl hydrocarbon receptor signaling in esophageal squamous cell carcinoma development and immune escape.** This figure illustrates the multifaceted influence of aryl hydrocarbon receptor (AhR) signaling on esophageal squamous cell carcinoma (ESCC) development and immune escape. Activation of AhR by environmental carcinogens or other ligands initiates a cascade of cellular processes that contribute to tumorigenesis. EMT: Epithelial-mesenchymal transition; NH3: Ammonia; PD-L1: Programmed death-ligand 1; ROS: Reactive oxygen species; TEPA: Triethylenetetramine.

## ARYL HYDROCARBON RECEPTOR SIGNALING: A MASTER REGULATOR WITH DIVERSE FUNCTIONS IN HEALTH AND DISEASE

Aryl hydrocarbon receptor (AhR) is a ubiquitous and complicated ligand-activated transcription factor that has significant influences on various physiological processes[17]. AhR, which is primarily found in the cytoplasm with chaperone proteins, goes through significant changes upon binding to ligands[18]. These ligands are categorized into two main groups: Exogenous, which includes environmental pollutants such as polycyclic aromatic hydrocarbons (PAHs), and endogenous, which comprises metabolites from tryptophan breakdown, such as tryptophan and kynurenine[19]. When a ligand binds, AhR alters its shape, releases from its chaperone complex, and moves to the nucleus[20]. It pairs with ARNT and attaches to specific DNA sequences called xenobiotic response elements in the regulatory regions of the target genes. This interaction initiates the transcription of various genes, influencing several cellular processes *via* AhR signaling[21]. Beyond its well-recognized role in xenobiotic metabolism, AhR signaling applies an excessive influence on numerous biological processes, including cellular proliferation and differentiation[22], angiogenesis[23], cellular metabolism[24], oxidative stress response[25], immune regulation[26], and inflammation[27].

Studies have demonstrated that AhR signaling affects the proliferation and differentiation of epithelial cells, lymphocytes, and hematopoietic progenitor cells[22]. Moreover, AhR may influence the expression of pro-angiogenic factors such as vascular endothelial growth factor, and impact both physiological and pathological angiogenesis[23]. AhR activation also influences insulin sensitivity, glucose uptake, and lipogenesis. Dysregulation of these pathways may contribute to the development of metabolic disorders, such as obesity and type 2 diabetes[24]. AhR signaling can influence cellular metabolism and, promote the Warburg effect. This metabolic shift not only enhances tumor cell proliferation, but can also create an immunosuppressive microenvironment by changing the levels of metabolites and signaling molecules that modulate immune cells[28]. The cellular environment is consistently influenced by the reactive oxygen species produced during normal metabolic processes. AhR can modulate the antioxidant defense system by targeting the expression of enzymes such as heme oxygenase-1, NAD, and quinone oxidoreductase 1, which are important in protecting cells from oxidative damage[25].

AhR signaling exerts a detailed and context-specific influence on the immune system. It modulates the function of several immune cell populations, including T cells, B cells, and antigen-presenting cells (APCs)[26]. AhR activation can promote the differentiation of Tregs with immunosuppressive properties, while simultaneously inhibiting the proliferation and function of effector T cells[29]. AhR can influence the expression of MHC, and co-stimulatory molecules on APCs, and impact the efficiency of antigen presentation and T cell activation[30]. The tumor microenvironment is often characterized by chronic inflammation, which can promote tumorigenesis. AhR signaling can influence the expression of inflammatory mediators, such as cytokines and chemokines, forming an inflammatory milieu within the tumor microenvironment. While some inflammatory responses can promote anti-tumor immunity, chronic inflammation initiated by aberrant AhR activation can create a pro-tumorigenic microenvironment[27]. The multi-dimensional nature of the AhR highlights its potential as a double-edged sword. While it contributes to essential physiological processes, including xenobiotic metabolism, immune homeostasis, and tissue development, its dysregulation can be involved in various disease pathologies, including cancer. Understanding the important role of AhR signaling in ESCC, especially its

influence on the tumor immune microenvironment and immune escape mechanisms, could be beneficial in the development of novel therapeutic strategies.

## AHR AND ESCC DEVELOPMENT

Exposure to environmental carcinogens, such as PAHs found in cigarette smoke and certain dietary components is a well-established risk factor for ESCC development[31]. These carcinogens can activate AhR signaling *via* direct ligand binding [32]. The activated AhR pathway influences multiple cellular processes that contribute to ESCC tumorigenesis. Studies have demonstrated that AhR activation can promote the proliferation of esophageal epithelial cells by modulating cell cycle regulatory proteins such as cyclin D1 and p21[33]. Moreover, AhR signaling can inhibit apoptosis and, the programmed cell death pathway, by influencing the expression of anti-apoptotic factors such as Bcl-2[34]. These effects create conditions favorable for deregulated cell proliferation, which is a characteristic of cancer. Chronic exposure to carcinogens can induce DNA damage in esophageal epithelial cells[35]. However, AhR activation can further exacerbate this issue by downregulating the expression of key DNA repair enzymes[36]. This impaired repair system increases the accumulation of mutations and, eventually increases the risk of malignant transformation. Cancer cells exhibit a distinct metabolic profile compared to healthy cells. ESCC development and progression may be initiated by a subpopulation of cancer stem cells with self-renewal and differentiation capabilities[37,38]. AhR activation has been studied in promoting the stemness properties of ESCC cells[39].

Epithelial-mesenchymal transition (EMT) is a critical process by which epithelial cells lose their polarized phenotype and acquire mesenchymal characteristics, gaining migratory and invasive potential[40]. AhR activation has been shown to induce EMT in various cell types, including esophageal epithelial cells[41]. Studies have demonstrated that AhR ligands can upregulate the expression of EMT-inducing transcription factors such as Twist1 and Snail, promoting the acquisition of an invasive phenotype by cancer cells[42]. The EMT process is crucial for ESCC progression and metastasis, by enabling cancer cells to detach from the primary tumor, migrate through the basement membrane, and invade the surrounding tissues and lymphatic vessels. EMT can also enhance the resistance of ESCC cells to anoikis, a type of cell death triggered by detachment from the extracellular matrix[43]. This combined effect of increased motility and resistance to anoikis promotes the dissemination of ESCC cells to other organs, resulting in the formation of metastases.

## AHR AND IMMUNE ESCAPE IN ESCC

While certain studies have indicated that activating AhR might enhance anti-cancer immune responses, other studies suggest its possible involvement in immune evasion mechanisms in ESCC. AhR activation can suppress effector T cells, the main attacking cells of the adaptive immune response[44]. Studies have shown that some AhR ligands can inhibit the proliferation and cytokine production of CD8+ CTLs and weaken the immune response against ESCC cells[45]. Additionally, AhR activation can promote the differentiation of Tregs, a population of immunosuppressive T cells that dampens the anti-tumor immune response[46]. The tumor microenvironment in ESCC is often infiltrated by immunosuppressive myeloid cells, including MDSCs[13]. AhR activation promotes the recruitment and expansion of MDSCs, which contributes to the suppression of anti-tumor immunity[47]. Immune checkpoint molecules, such as PD-L1 and CTLA-4, act as inhibitory agents in the immune system to prevent autoimmunity. However, ESCC cells can use these checkpoints to escape immune response[48]. Some studies suggested that AhR activation upregulates the expression of PD-L1 on ESCC cells, potentially participating in immune escape by inhibiting T cell function[49]. **Table 1** summarizes the influence of AhR signaling on ESCC development, progression, and immune escape.

## THERAPEUTIC POTENTIAL OF TARGETING AHR SIGNALING IN ESCC

The complex influence of AhR signaling on ESCC development, progression, and immune escape presents an interesting opportunity for the development of novel therapeutic strategies. While the aberrant AhR activation can promote tumorigenesis and create an immunosuppressive microenvironment, its proper modulation could be beneficial for disrupting these processes and boosting the anti-tumor immune response.

Preclinical studies investigating AhR ligands in ESCC models have yielded in interesting results[49]. Several antagonists could competitively bind to the ligand-binding domain, and block the activation of AhR signaling pathways and their downstream effects on ESCC cells[49]. Studies have demonstrated that AhR antagonists can suppress ESCC cell proliferation, migration, and invasion, potentially inhibiting tumor progression and metastasis[50]. AhR antagonists exhibit immunomodulatory effects within the tumor microenvironment, by inhibiting AhR signaling. These antagonists may reduce the population of immunosuppressive MDSCs and Tregs, and simultaneously enhancing the function and proliferation of effector T cells, leading to a more powerful anti-tumor immune response[51,52]. Several AhR antagonists are currently under investigation for their therapeutic potential in ESCC, including CH-223191, NH3 (Ammonia), and specific small molecules[53]. Not only AhR antagonists but also some naturally derived AhR agonists, such as curcumin [54] and quercetin[55] have been shown to exhibit regulatory properties on immune response in cancer. This controversy could be due to the structural and metabolic differences of different AhR ligands. Furthermore, synthetic AhR antagonists are being actively developed, with some demonstrating promising preclinical results[51]. **Table 2** has summarized some



**Table 1 Aryl hydrocarbon receptor signaling and its impact on**

Aspect of ESCC	Impact of AhR activation	Mechanism	Ref.
Carcinogenesis			
Proliferation	Increased	Upregulates cyclin D1, downregulates p21	[31,33]
Apoptosis	Inhibited	Upregulates anti-apoptotic factors like Bcl-2	[34]
DNA repair	Impaired	Downregulates expression of key DNA repair enzymes	[36]
Metabolic reprogramming	Promotes Warburg effect	Increases reliance on aerobic glycolysis	[28]
Stemness	Enhanced	Promotes self-renewal and differentiation of cancer stem cells	[37,38]
EMT	Induced	Upregulates EMT-inducing transcription factors like Twist1 and Snail	[41,43]
Immune escape			
T cell function	Suppressed	Inhibits proliferation and cytokine production of CD8+ CTLs, promotes differentiation of Tregs	[45,46]
Myeloid cell recruitment	Increased	Promotes recruitment and expansion of MDSCs	[47]
Immune checkpoint regulation	Potential upregulation of PD-L1 expression	May contribute to immune escape by inhibiting T cell activity	[49]

AhR: Aryl hydrocarbon receptor; Bcl-2: B-cell lymphoma 2; CD8+ CTLs: CD8+ Cytotoxic T lymphocytes; EMT: Epithelial-mesenchymal transition; ESCC: Esophageal squamous cell carcinoma; MDSCs: Myeloid-derived suppressor cells; PD-L1: Programmed death-ligand 1; Snail: Zinc finger protein SNAIL; Twist1: Twist family BHLH Transcription factor 1; Tregs: Regulatory T cells.

**Table 2 Mechanisms of action and potential effects of promising aryl hydrocarbon receptor antagonists on malignancies**

AhR ligands	Mechanism of action	Potential effects on malignancies	Ref.
Natural products			
Curcumin	Competitive binding to the AhR ligand-binding domain	Suppresses proliferation, migration, and invasion of cancer cells; may enhance anti-tumor immunity	[54,62,63]
Quercetin	Competitive binding to the AhR ligand-binding domain; may also inhibit AhR nuclear translocation	Suppresses proliferation and induces apoptosis in cancer cells	[55]
Resveratrol	May interfere with AhR-DNA binding; may also possess antioxidant and anti-inflammatory properties	May inhibit tumor growth and metastasis	[55,64]
Synthetic ligands			
CH-223191	Competitive binding to the AhR ligand-binding domain	Suppresses proliferation and migration of cancer cells	[65]
NH3 (Ammonia)	Competitive binding to the AhR ligand-binding domain	Shows promise in preclinical models, but may have limitations due to potential toxicity	[66]
Small molecule antagonists	Competitive binding to the AhR ligand-binding domain or interfering with AhR dimerization	Several novel small molecules are under development, with preclinical studies ongoing	[67,68]

AhR: Aryl hydrocarbon receptor.

of the most promising candidates, their mechanisms of action, and potential effects on malignancies.

Beyond directly targeting the AhR itself, manipulating the endogenous ligands that activate this pathway offers another potential therapeutic avenue. The gut microbiota plays an important role in metabolizing dietary components into ligands that can activate AhR signaling[56]. Strategies aimed at modulating the gut microbiota composition, potentially through prebiotics or probiotics, could be studied to influence the production of these ligands and their subsequent impact on AhR signaling in ESCC[57]. Moreover, dietary factors can also influence AhR ligand production. Identifying and employing natural AhR modulators, such as indole-3-carbinol found in cruciferous vegetables, into the diet could be a preventive or complementary therapeutic approach for ESCC patients[58,59]. Some AhR agonists such as TCDD bind tightly to the AhR, leading to long-lasting activation that disrupts normal cellular processes and promotes cancer development. However, I3C, and its metabolites transiently activate the AhR. This controlled activation helps in detoxifying carcinogens, inhibiting abnormal cell growth, and promoting cancer cell death, highlighting their potential anticancer effects[58,59]. However, the effectiveness of dietary AhR modulators is not well-established by the lack of

comprehensive studies on the metabolic kinetics, permeability, and transport of dietary compounds. Future research should focus on these aspects to better understand and optimize the role of these compounds on ESCC treatment.

The therapeutic potential of AhR-targeted strategies may be further intensified when combined with existing treatment approaches for ESCC. For instance, combining selected AhR ligands (agonist or antagonist) with conventional therapies such as surgery, radiation, or chemotherapy could offer synergistic effects. These traditional therapies can induce DNA damage and cell death in ESCC cells, while AhR ligands may suppress tumor growth and metastasis by inhibiting proliferation and invasion[60]. Additionally, AhR ligands could be particularly effective when combined with immune checkpoint inhibitors[61]. Clinical trials investigating the combination of AhR-targeted therapies with other treatment strategies are suggested to determine their efficacy and safety in ESCC patients.

---

## CONCLUSION

Immune escape mechanisms play a crucial role in ESCC progression, allowing cancer cells to evade the surveillance of the host immune system. The AhR activation, triggered by environmental carcinogens such as PAHs, promotes various hallmarks of cancer, including proliferation, apoptosis inhibition, and metabolic reprogramming. Moreover, AhR signaling contributes to immune escape by suppressing T cell function, recruiting immunosuppressive myeloid cells, and upregulating immune checkpoint molecules like PD-L1. Targeting AhR signaling presents a promising therapeutic approach for ESCC. AhR ligands (agonist or antagonist), both natural and synthetic, have shown potential in preclinical studies by inhibiting tumor growth and modulating the immune microenvironment. Modulating AhR ligands through dietary interventions may offer new therapeutic approaches. Furthermore, combining AhR-targeted therapies with conventional treatments or immune checkpoint inhibitors may result in synergistic effects, enhancing overall therapeutic efficacy.

---

## FOOTNOTES

**Author contributions:** Rahmati M and Moghtaderi H reviewed the literature, prepared information, and drafted the manuscript; Mohammadi S and Al-Harrasi A conceptualized the review, proposed the title, and provided critical reviews; All authors have read and approved the final manuscript. Rahmati M and Moghtaderi H reviewed relevant literature, gathered essential information, and drafted the initial version of the manuscript. Rahmati M organized the data and ensured the integration of comprehensive and relevant studies into the review. Moghtaderi H synthesized the gathered information and contributed significantly to the initial manuscript draft. Mohammadi S and Al-Harrasi A conceptualized the overall scope of the review article and proposed the title. Mohammadi S offered essential perspectives that maintained the manuscript's logical flow and improved its scientific precision during the revision stages. Al-Harrasi A conducted extensive reviews and contributed to revising the content to meet high academic standards. Both Rahmati M and Moghtaderi H made crucial contributions towards the completion of the review, qualifying as co-first authors. Both Mohammadi S and Al-Harrasi A played important and essential roles in the conceptual design, critical review, and manuscript preparation as co-corresponding authors. Mohammadi S supervised the entire review process, provided continuous oversight, and ensured the manuscript's coherence. Al-Harrasi A contributed significantly to the critical review, enhancing the manuscript's quality and accuracy. This collaboration between Mohammadi S and Al-Harrasi A was essential for the successful completion and publication of this manuscript. Their combined efforts in conceptual design, critical review, and supervision were crucial for maintaining the manuscript's high standards and academic integrity.

**Conflict-of-interest statement:** All the authors declare that there are no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country of origin:** Oman

**ORCID number:** Mina Rahmati 0000-0002-1151-2437; Hassan Moghtaderi 0000-0002-1804-8251; Saeed Mohammadi 0000-0001-9895-8468; Ahmed Al-Harrasi 0000-0003-0317-8448.

**S-Editor:** Liu JH

**L-Editor:** Filipodia

**P-Editor:** Wang WB

---

## REFERENCES

- 1 **Sheikh M**, Roshandel G, McCormack V, Malekzadeh R. Current Status and Future Prospects for Esophageal Cancer. *Cancers (Basel)* 2023; **15** [PMID: 36765722 DOI: 10.3390/cancers15030765]
- 2 **Tungekar A**, Mandarthi S, Mandaviya PR, Gadekar VP, Tantry A, Kotian S, Reddy J, Prabha D, Bhat S, Sahay S, Mascarenhas R, Badkillaya RR, Nagasampige MK, Yelnadu M, Pawar H, Hebbar P, Kashyap MK. ESCC ATLAS: A population wide compendium of biomarkers for

- Esophageal Squamous Cell Carcinoma. *Sci Rep* 2018; **8**: 12715 [PMID: 30143675 DOI: 10.1038/s41598-018-30579-3]
- 3 Testa U, Castelli G, Pelosi E. Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. *Medicines (Basel)* 2017; **4** [PMID: 28930282 DOI: 10.3390/medicines4030067]
- 4 Tarazi M, Chidambaram S, Markar SR. Risk Factors of Esophageal Squamous Cell Carcinoma beyond Alcohol and Smoking. *Cancers (Basel)* 2021; **13** [PMID: 33671026 DOI: 10.3390/cancers13051009]
- 5 Mandard AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. *Mutat Res* 2000; **462**: 335-342 [PMID: 10767643 DOI: 10.1016/S1383-5742(00)00019-3]
- 6 Shi Y, Li MY, Wang H, Li C, Liu WY, Gao YM, Wang B, Song JW, Ma YQ. The Relationship between MACC1/c-Met/Cyclin D1 Axis Expression and Prognosis in ESCC. *Anal Cell Pathol (Amst)* 2022; **2022**: 9651503 [PMID: 35242498 DOI: 10.1155/2022/9651503]
- 7 Liu WJ, Zhao Y, Chen X, Miao ML, Zhang RQ. Epigenetic modifications in esophageal cancer: An evolving biomarker. *Front Genet* 2022; **13**: 1087479 [PMID: 36704345 DOI: 10.3389/fgene.2022.1087479]
- 8 Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B, Hu R, Hao J, Bai S, Xiao H, Li WV, Bueker A, Ma Y, Xie G, Yang J, Chen S, Li H, Cao J, Shen L. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. *Nat Commun* 2020; **11**: 6268 [PMID: 33293583 DOI: 10.1038/s41467-020-20019-0]
- 9 Tang S, Ning Q, Yang L, Mo Z, Tang S. Mechanisms of immune escape in the cancer immune cycle. *Int Immunopharmacol* 2020; **86**: 106700 [PMID: 32590316 DOI: 10.1016/j.intimp.2020.106700]
- 10 Li R, Huang B, Tian H, Sun Z. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. *Front Oncol* 2022; **12**: 1096717 [PMID: 36698392 DOI: 10.3389/fonc.2022.1096717]
- 11 Zhang XJ, Yu Y, Zhao HP, Guo L, Dai K, Lv J. Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer. *World J Gastroenterol* 2024; **30**: 2195-2208 [PMID: 38690024 DOI: 10.3748/wjg.v30.i16.2195]
- 12 Garrido F, Aptsiauri N. Cancer immune escape: MHC expression in primary tumours versus metastases. *Immunology* 2019; **158**: 255-266 [PMID: 31509607 DOI: 10.1111/imm.13114]
- 13 Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Baba H. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. *Cancer Sci* 2020; **111**: 3132-3141 [PMID: 32579769 DOI: 10.1111/cas.14541]
- 14 Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. *J Exp Clin Cancer Res* 2021; **40**: 184 [PMID: 34088360 DOI: 10.1186/s13046-021-01987-7]
- 15 Mahmoudian RA, Mozgani S, Abbaszadegan MR, Mokhlessi L, Montazer M, Gholamin M. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. *J Mol Histol* 2021; **52**: 597-609 [PMID: 33884540 DOI: 10.1007/s10735-021-09971-3]
- 16 Liu J, Lu G, Tang F, Liu Y, Cui G. Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. *Virchows Arch* 2009; **455**: 441-448 [PMID: 19844741 DOI: 10.1007/s00428-009-0846-3]
- 17 Kou Z, Dai W. Aryl hydrocarbon receptor: Its roles in physiology. *Biochem Pharmacol* 2021; **185**: 114428 [PMID: 33515530 DOI: 10.1016/j.bcp.2021.114428]
- 18 Denison MS, Pandini A, Nagy SR, Baldwin EP, Bonati L. Ligand binding and activation of the Ah receptor. *Chem Biol Interact* 2002; **141**: 3-24 [PMID: 12213382 DOI: 10.1016/S0009-2797(02)00063-7]
- 19 Safe S, Jin UH, Park H, Chapkin RS, Jayaraman A. Aryl Hydrocarbon Receptor (AHR) Ligands as Selective AHR Modulators (SAhRMs). *Int J Mol Sci* 2020; **21** [PMID: 32932962 DOI: 10.3390/ijms21186654]
- 20 Safe S, Han H, Goldsby J, Mohankumar K, Chapkin RS. Aryl Hydrocarbon Receptor (AhR) Ligands as Selective AhR Modulators: Genomic Studies. *Curr Opin Toxicol* 2018; **11-12**: 10-20 [PMID: 31453421 DOI: 10.1016/j.cotox.2018.11.005]
- 21 Kerkvliet NI. AHR-mediated immunomodulation: the role of altered gene transcription. *Biochem Pharmacol* 2009; **77**: 746-760 [PMID: 19100241 DOI: 10.1016/j.bcp.2008.11.021]
- 22 Yin J, Sheng B, Qiu Y, Yang K, Xiao W, Yang H. Role of AhR in positive regulation of cell proliferation and survival. *Cell Prolif* 2016; **49**: 554-560 [PMID: 27523394 DOI: 10.1111/cpr.12282]
- 23 Li Y, Wang K, Zou QY, Jiang YZ, Zhou C, Zheng J. ITE Suppresses Angiogenic Responses in Human Artery and Vein Endothelial Cells: Differential Roles of AhR. *Reprod Toxicol* 2017; **74**: 181-188 [PMID: 28986273 DOI: 10.1016/j.reprotox.2017.09.010]
- 24 Bock KW. Aryl hydrocarbon receptor (AHR) functions in NAD(+) metabolism, myelopoiesis and obesity. *Biochem Pharmacol* 2019; **163**: 128-132 [PMID: 30779909 DOI: 10.1016/j.bcp.2019.02.021]
- 25 Huang Y, Zhang J, Tao Y, Ji C, Aniagu S, Jiang Y, Chen T. AHR/ROS-mediated mitochondria apoptosis contributes to benzo[a]pyrene-induced heart defects and the protective effects of resveratrol. *Toxicology* 2021; **462**: 152965 [PMID: 34597721 DOI: 10.1016/j.tox.2021.152965]
- 26 Hao N, Whitelaw ML. The emerging roles of AhR in physiology and immunity. *Biochem Pharmacol* 2013; **86**: 561-570 [PMID: 23856287 DOI: 10.1016/j.bcp.2013.07.004]
- 27 Neavin DR, Liu D, Ray B, Weinsilboum RM. The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases. *Int J Mol Sci* 2018; **19** [PMID: 30513921 DOI: 10.3390/ijms19123851]
- 28 Gabrieli G, Wheeler MA, Takenaka MC, Quintana FJ. Role of AHR and HIF-1 $\alpha$  in Glioblastoma Metabolism. *Trends Endocrinol Metab* 2017; **28**: 428-436 [PMID: 28318896 DOI: 10.1016/j.tem.2017.02.009]
- 29 Liu X, Hu H, Fan H, Zuo D, Shou Z, Liao Y, Nan Z, Tang Q. The role of STAT3 and AhR in the differentiation of CD4+ T cells into Th17 and Treg cells. *Medicine (Baltimore)* 2017; **96**: e6615 [PMID: 28445259 DOI: 10.1097/MD.00000000000006615]
- 30 Mohammadi S, Memarian A, Sedighi S, Behnampour N, Yazdani Y. Immunoregulatory effects of indole-3-carbinol on monocyte-derived macrophages in systemic lupus erythematosus: A crucial role for aryl hydrocarbon receptor. *Autoimmunity* 2018; **51**: 199-209 [PMID: 30289282 DOI: 10.1080/08916934.2018.1494161]
- 31 Abedi-Ardekani B, Kamangar F, Hewitt SM, Hainaut P, Sotoudeh M, Abnet CC, Taylor PR, Boffetta P, Malekzadeh R, Dawsey SM. Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. *Gut* 2010; **59**: 1178-1183 [PMID: 20584779 DOI: 10.1136/gut.2010.210609]
- 32 Wang Z, Snyder M, Kenison JE, Yang K, Lara B, Lydell E, Bennani K, Novikov O, Federico A, Monti S, Sherr DH. How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression. *Int J Mol Sci* 2020; **22** [PMID: 33396563 DOI: 10.3390/ijms22010387]
- 33 Liu J, Min L, Zhu S, Guo Q, Li H, Zhang Z, Zhao Y, Xu C, Zhang S. Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by

- Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma. *J Cancer* 2019; **10**: 1915-1922 [PMID: 31205550 DOI: 10.7150/jca.27053]
- 34 **Al-Dhfyar A**, Alaiya A, Al-Mohanna F, Attwa MW, AlAsmari AF, Bakheet SA, Korashy HM. Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy. *J Adv Res* 2023; **50**: 177-192 [PMID: 36307019 DOI: 10.1016/j.jare.2022.10.006]
- 35 **Bai H**, Wu M, Zhang H, Tang G. Chronic polycyclic aromatic hydrocarbon exposure causes DNA damage and genomic instability in lung epithelial cells. *Oncotarget* 2017; **8**: 79034-79045 [PMID: 29108285 DOI: 10.18632/oncotarget.20891]
- 36 **Pollet M**, Shaik S, Mescher M, Frauenstein K, Tigges J, Braun SA, Sondenheimer K, Kaveh M, Bruhs A, Meller S, Homey B, Schwarz A, Esser C, Douki T, Vogel CFA, Krutmann J, Haarmann-Stemmann T. The AHR represses nucleotide excision repair and apoptosis and contributes to UV-induced skin carcinogenesis. *Cell Death Differ* 2018; **25**: 1823-1836 [PMID: 30013037 DOI: 10.1038/s41418-018-0160-1]
- 37 **Wu Q**, Wu Z, Bao C, Li W, He H, Sun Y, Chen Z, Zhang H, Ning Z. Cancer stem cells in esophageal squamous cell cancer. *Oncol Lett* 2019; **18**: 5022-5032 [PMID: 31612013 DOI: 10.3892/ol.2019.10900]
- 38 **Khosravi A**, Jafari SM, Asadi J. Knockdown of TAZ decrease the cancer stem properties of ESCC cell line YM-1 by modulation of Nanog, OCT-4 and SOX2. *Gene* 2021; **769**: 145207 [PMID: 33031893 DOI: 10.1016/j.gene.2020.145207]
- 39 **Wu C**, Yu S, Tan Q, Guo P, Liu H. Role of AhR in regulating cancer stem cell-like characteristics in choriocarcinoma. *Cell Cycle* 2018; **17**: 2309-2320 [PMID: 30311543 DOI: 10.1080/15384101.2018.1535219]
- 40 **Brabletz T**, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. *Nat Rev Cancer* 2018; **18**: 128-134 [PMID: 29326430 DOI: 10.1038/nrc.2017.118]
- 41 **Zhu P**, Yu H, Zhou K, Bai Y, Qi R, Zhang S. 3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE(2) pathway. *J Exp Clin Cancer Res* 2020; **39**: 113 [PMID: 32546278 DOI: 10.1186/s13046-020-01618-7]
- 42 **Chuang KT**, Chiou SS, Hsu SH. Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial-Mesenchymal Transition. *Cancers (Basel)* 2023; **15** [PMID: 37444447 DOI: 10.3390/cancers15133338]
- 43 **Liao C**, Wang Q, An J, Long Q, Wang H, Xiang M, Xiang M, Zhao Y, Liu Y, Liu J, Guan X. Partial EMT in Squamous Cell Carcinoma: A Snapshot. *Int J Biol Sci* 2021; **17**: 3036-3047 [PMID: 34421348 DOI: 10.7150/ijbs.61566]
- 44 **Zhang H**, Yang Z, Yuan W, Liu J, Luo X, Zhang Q, Li Y, Chen J, Zhou Y, Lv J, Zhou N, Ma J, Tang K, Huang B. Sustained AhR activity programs memory fate of early effector CD8(+) T cells. *Proc Natl Acad Sci U S A* 2024; **121**: e2317658121 [PMID: 38437537 DOI: 10.1073/pnas.2317658121]
- 45 **Wang G**, Pan C, Cao K, Zhang J, Geng H, Wu K, Wen J, Liu C. Impacts of Cigarette Smoking on the Tumor Immune Microenvironment in Esophageal Squamous Cell Carcinoma. *J Cancer* 2022; **13**: 413-425 [PMID: 35069891 DOI: 10.7150/jca.65400]
- 46 **Leclerc D**, Staats Pires AC, Guillemin GJ, Gilot D. Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies. *Curr Opin Immunol* 2021; **70**: 15-26 [PMID: 33429228 DOI: 10.1016/j.coi.2020.12.003]
- 47 **Neamah WH**, Singh NP, Alghetaa H, Abdulla OA, Chatterjee S, Busbee PB, Nagarkatti M, Nagarkatti P. AhR Activation Leads to Massive Mobilization of Myeloid-Derived Suppressor Cells with Immunosuppressive Activity through Regulation of CXCR2 and MicroRNA miR-150-5p and miR-543-3p That Target Anti-Inflammatory Genes. *J Immunol* 2019; **203**: 1830-1844 [PMID: 31492743 DOI: 10.4049/jimmunol.1900291]
- 48 **Banday AH**, Abdalla M. Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. *Curr Med Chem* 2023; **30**: 3215-3237 [PMID: 35986535 DOI: 10.2174/0929867329666220819115849]
- 49 **Zhu P**, Zhou K, Lu S, Bai Y, Qi R, Zhang S. Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2/PGE2/STAT3 axis. *J Cell Commun Signal* 2020; **14**: 175-192 [PMID: 31925646 DOI: 10.1007/s12079-019-00535-5]
- 50 **To KK**, Yu L, Liu S, Fu J, Cho CH. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. *Mol Carcinog* 2012; **51**: 449-464 [PMID: 21678497 DOI: 10.1002/mc.20810]
- 51 **Baker JR**, Sakoff JA, McCluskey A. The aryl hydrocarbon receptor (AhR) as a breast cancer drug target. *Med Res Rev* 2020; **40**: 972-1001 [PMID: 31721255 DOI: 10.1002/med.21645]
- 52 **Sun L**. Recent advances in the development of AHR antagonists in immuno-oncology. *RSC Med Chem* 2021; **12**: 902-914 [PMID: 34223158 DOI: 10.1039/d1md00015b]
- 53 **Safe S**, Zhang L. The Role of the Aryl Hydrocarbon Receptor (AhR) and Its Ligands in Breast Cancer. *Cancers (Basel)* 2022; **14** [PMID: 36428667 DOI: 10.3390/cancers14225574]
- 54 **Nakai R**, Fukuda S, Kawase M, Yamashita Y, Ashida H. Curcumin and its derivatives inhibit 2,3,7,8,-tetrachloro-dibenzo-p-dioxin-induced expression of drug metabolizing enzymes through aryl hydrocarbon receptor-mediated pathway. *Biosci Biotechnol Biochem* 2018; **82**: 616-628 [PMID: 29191105 DOI: 10.1080/09168451.2017.1386086]
- 55 **Mohammadi-Bardbori A**, Bengtsson J, Rannug U, Rannug A, Wincent E. Quercetin, resveratrol, and curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). *Chem Res Toxicol* 2012; **25**: 1878-1884 [PMID: 22867086 DOI: 10.1021/tx300169e]
- 56 **Dai G**, Chen X, He Y. The Gut Microbiota Activates AhR Through the Tryptophan Metabolite Kyn to Mediate Renal Cell Carcinoma Metastasis. *Front Nutr* 2021; **8**: 712327 [PMID: 34458309 DOI: 10.3389/fnut.2021.712327]
- 57 **Yang F**, DeLuca JAA, Menon R, Garcia-Vilarato E, Callaway E, Landrock KK, Lee K, Safe SH, Chapkin RS, Allred CD, Jayaraman A. Effect of diet and intestinal AhR expression on fecal microbiome and metabolomic profiles. *Microb Cell Fact* 2020; **19**: 219 [PMID: 33256731 DOI: 10.1186/s12934-020-01463-5]
- 58 **Peng C**, Wu C, Xu X, Pan L, Lou Z, Zhao Y, Jiang H, He Z, Ruan B. Indole-3-carbinol ameliorates necroptosis and inflammation of intestinal epithelial cells in mice with ulcerative colitis by activating aryl hydrocarbon receptor. *Exp Cell Res* 2021; **404**: 112638 [PMID: 34015312 DOI: 10.1016/j.yexcr.2021.112638]
- 59 **Mohammadi S**, Seyedhosseini FS, Behnampour N, Yazdani Y. Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line. *J Recept Signal Transduct Res* 2017; **37**: 506-514 [PMID: 28812970 DOI: 10.1080/10799893.2017.1360351]
- 60 **Bayat Mokhtari R**, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeager H. Combination therapy in combating cancer. *Oncotarget* 2017; **8**: 38022-38043 [PMID: 28410237 DOI: 10.18632/oncotarget.16723]
- 61 **Tan N**, Zhao W, Wang Y, Li P, Liu J, Sun Z, Pan J, Song S, Li S, Liu Z, Bian Y. AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma. *J Cancer Res Clin Oncol* 2023; **149**: 9705-9720 [PMID: 37233762 DOI: 10.1007/s00432-023-04633-9]



- 10.1007/s00432-023-04894-w]
- 62 **Bahrami A**, Majeed M, Sahebkar A. Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition. *Cell Oncol (Dordr)* 2019; **42**: 405-421 [PMID: 30980365 DOI: 10.1007/s13402-019-00442-2]
- 63 **Ang HL**, Mohan CD, Shanmugam MK, Leong HC, Makvandi P, Rangappa KS, Bishayee A, Kumar AP, Sethi G. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. *Med Res Rev* 2023; **43**: 1141-1200 [PMID: 36929669 DOI: 10.1002/med.21948]
- 64 **Jin Z**, Feng W, Ji Y, Jin L. Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway. *Oncol Lett* 2017; **13**: 347-355 [PMID: 28123566 DOI: 10.3892/ol.2016.5391]
- 65 **Choi EY**, Lee H, Dingle RW, Kim KB, Swanson HI. Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor. *Mol Pharmacol* 2012; **81**: 3-11 [PMID: 21967751 DOI: 10.1124/mol.111.073643]
- 66 **Wu H**, Ma W, Wang Y, Wang Y, Sun X, Zheng Q. Gut microbiome-metabolites axis: A friend or foe to colorectal cancer progression. *Biomed Pharmacother* 2024; **173**: 116410 [PMID: 38460373 DOI: 10.1016/j.biopha.2024.116410]
- 67 **Kober C**, Roewe J, Schmees N, Roese L, Roehn U, Bader B, Stoeckigt D, Prinz F, Gorjánác M, Roider HG, Olesch C, Leder G, Irlbacher H, Lesche R, Lefranc J, Oezcan-Wahlbrink M, Batra AS, Elmadany N, Carretero R, Sahn K, Oezen I, Cichon F, Baumann D, Sadik A, Opitz CA, Weinmann H, Hartung IV, Kreft B, Offringa R, Platten M, Gutcher I. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy. *J Immunother Cancer* 2023; **11** [PMID: 37963637 DOI: 10.1136/jitc-2023-007495]
- 68 **Joseph J**, Gonzalez-lopez M, Galang C, Garcia C, Lemar H, Lu J, Vaidya K, Fischer M, Frey C, Alam M, Yao B, Dillon M, Hager JH, Venetsanakos E, Aswad F. Abstract 4719: Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs *in vitro* and demonstrate significant impact on tumor growth and immune modulation *in vivo*. *Cancer Res* 2018; **78**: 4719-4719 [DOI: 10.1158/1538-7445.AM2018-4719]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

